Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Thermo Fisher Scientific Inc. pages available for free this week:
- Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Liquidity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Capital Asset Pricing Model (CAPM)
- Dividend Discount Model (DDM)
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Thermo Fisher Scientific Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Short-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
An analysis of the operating activity ratios reveals a general trend of efficiency improvement in inventory management during the initial periods, followed by a phase of stabilization and slight volatility in the cash conversion cycle.
- Inventory Management
- Inventory turnover exhibited a consistent upward trend from 3.87 in April 2022 to a peak of 5.06 by December 2023. This improvement is mirrored in the average inventory processing period, which declined from 94 days to a low of 72 days over the same timeframe. From 2024 through June 2026, these metrics stabilized, with the processing period fluctuating between 72 and 82 days, indicating a sustained, though less aggressive, optimization of stock levels.
- Receivables and Collections
- Receivables turnover remained relatively stable but showed a gradual decline from 5.21 in early 2022 to 4.90 by June 2026. Correspondingly, the average receivable collection period shifted from 70 days to 74 days. This slight increase suggests a marginal slowing in the speed of collecting payments from customers over the analyzed period.
- Payables and Supplier Relations
- Payables turnover demonstrated significant volatility, peaking at 10.82 in July 2023 before trending downward to 8.39 by June 2026. The average payables payment period reflected this instability, dropping to a minimum of 34 days in July 2023 and reaching a maximum of 50 days by December 2025. These fluctuations indicate periodic shifts in supplier payment strategies or changes in credit terms.
- Working Capital and Operating Cycles
- The working capital turnover ratio experienced a sharp spike to 10.13 in April 2023, followed by a general decline and subsequent volatility, ending at 5.59 in June 2026. The operating cycle showed a compression from 164 days in April 2022 to approximately 142 days by December 2023, before settling around 149 days in the final quarters.
- Cash Conversion Cycle (CCC)
- The cash conversion cycle followed a similar trajectory to the operating cycle, decreasing from 118 days in April 2022 to 97 days by December 2023. In the subsequent period through June 2026, the CCC fluctuated between 98 and 112 days, eventually settling at 106 days. This suggests that while the company successfully reduced its cash-to-cash cycle in the first two years, it has since entered a period of equilibrium.
Turnover Ratios
Average No. Days
Inventory Turnover
| Jun 27, 2026 | Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Cost of revenues | ||||||||||||||||||||||||
| Inventories | ||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Inventory turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Inventory Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q2 2026 Calculation
Inventory turnover
= (Cost of revenuesQ2 2026
+ Cost of revenuesQ1 2026
+ Cost of revenuesQ4 2025
+ Cost of revenuesQ3 2025)
÷ Inventories
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of short-term operating activity indicates a general improvement in inventory management efficiency from early 2022 through 2026, characterized by an initial strengthening of the turnover ratio followed by a period of stabilization.
- Inventory Turnover Trend
- A consistent upward trajectory in the inventory turnover ratio is observed from April 2022, where the ratio stood at 3.87, peaking at 5.06 by December 2023. This period reflects a significant increase in the velocity at which inventory is converted into sales. Following this peak, the ratio experienced moderate volatility, dipping to a low of 4.47 in September 2025 before stabilizing at 4.87 through the first half of 2026.
- Inventory Level Dynamics
- Inventory levels exhibited a fluctuating pattern, initially rising from 5,483 million USD in April 2022 to a peak of 5,722 million USD in October 2022. A subsequent reduction phase occurred throughout 2023 and 2024, reaching a minimum of 4,978 million USD by December 2024. A secondary increase in stock levels is noted between March 2025 and September 2025, peaking at 5,745 million USD, which correlates with the observed temporary decline in the turnover ratio during the same period.
- Cost of Revenues Correlation
- The cost of revenues demonstrates cyclicality, with recurring peaks observed every December (e.g., 6,844 million USD in 2022, 6,573 million USD in 2024, and 7,204 million USD in 2025). The relationship between the rising cost of revenues and the inventory turnover ratio suggests that the organization has maintained operational efficiency even during periods of higher expenditure, with the turnover ratio remaining largely above 4.5 after the initial 2022 growth phase.
- Operational Efficiency Insight
- The transition from a turnover ratio of 3.87 to a sustained level near 4.87 indicates a permanent shift toward leaner inventory management. The ability to maintain a higher turnover ratio despite fluctuations in total inventory volume suggests an optimized alignment between procurement cycles and revenue generation.
Receivables Turnover
| Jun 27, 2026 | Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Revenues | ||||||||||||||||||||||||
| Accounts receivable, less allowances | ||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Receivables turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Receivables Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q2 2026 Calculation
Receivables turnover
= (RevenuesQ2 2026
+ RevenuesQ1 2026
+ RevenuesQ4 2025
+ RevenuesQ3 2025)
÷ Accounts receivable, less allowances
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of short-term operating activity indicates a gradual decline in the efficiency of receivables management over the period from April 2022 to June 2026.
- Receivables Turnover Trend
- The receivables turnover ratio exhibited an initial increase, reaching a peak of 5.76 in October 2022. Following this peak, the ratio remained relatively stable, fluctuating between 5.19 and 5.53 throughout 2023. A consistent downward trajectory emerged starting in 2024, with the ratio descending to 4.90 by June 2026. This movement suggests a slowing rate of collection relative to the volume of credit sales generated.
- Accounts Receivable Growth
- A steady expansion of the accounts receivable balance is observed, rising from 7,889 million USD in April 2022 to 9,451 million USD by June 2026. This growth in the asset balance represents a significant increase in the capital tied up in unpaid customer invoices over the analyzed timeframe.
- Revenue Correlation and Efficiency
- Quarterly revenues demonstrated moderate volatility, generally fluctuating between 10,300 million USD and 12,200 million USD. While revenue showed signs of recovery and growth toward the end of 2025 and early 2026, the concurrent increase in accounts receivable grew at a faster pace. This imbalance resulted in the compression of the turnover ratio, indicating that revenue growth was not matched by a corresponding increase in collection velocity.
The convergence of a rising receivables balance and a declining turnover ratio suggests a lengthening of the average collection period. This pattern indicates a potential shift in credit terms or a decrease in the efficiency of the credit-to-cash conversion cycle during the latter half of the observed period.
Payables Turnover
| Jun 27, 2026 | Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Cost of revenues | ||||||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Payables turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Payables Turnover, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q2 2026 Calculation
Payables turnover
= (Cost of revenuesQ2 2026
+ Cost of revenuesQ1 2026
+ Cost of revenuesQ4 2025
+ Cost of revenuesQ3 2025)
÷ Accounts payable
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The payables turnover ratio exhibits a cyclical pattern of volatility between April 2022 and June 2026, reflecting fluctuations in the efficiency and timing of supplier payments relative to the cost of revenues. The ratio demonstrates a period of acceleration in turnover followed by a sustained deceleration, before showing signs of a modest recovery in the first half of 2026.
- Turnover Ratio Fluctuations
- An initial upward trend is observed from April 2022, where the ratio stood at 7.96, peaking at 10.82 in July 2023. This peak represents the highest efficiency in settling payables during the analyzed period. Following this peak, a general downward trajectory occurred, reaching a minimum value of 7.27 by December 31, 2025.
- Correlation with Accounts Payable Balances
- Significant declines in the turnover ratio consistently align with periods of increased accounts payable balances. Notable spikes in liabilities are observed every December (2022, 2024, and 2025), which directly correlate with the periodic dips in the turnover ratio. This pattern suggests a seasonal accumulation of obligations at the end of the calendar year.
- Cost of Revenues Impact
- While the cost of revenues remains relatively stable, fluctuating primarily between 6.1 billion and 7.2 billion US dollars, the variations in the turnover ratio are more closely tied to the volatility of the accounts payable balance. The increase in cost of revenues to 7.2 billion in December 2025 was offset by a proportional increase in payables to 3.6 billion, resulting in the period's lowest turnover ratio.
- Recent Recovery Phase
- Following the low point in December 2025, a recovery trend is evident. The ratio increased to 8.00 in March 2026 and further to 8.39 by June 2026, indicating a return toward the historical mean and a potential tightening of the payment cycle.
Working Capital Turnover
| Jun 27, 2026 | Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Current assets | ||||||||||||||||||||||||
| Less: Current liabilities | ||||||||||||||||||||||||
| Working capital | ||||||||||||||||||||||||
| Revenues | ||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Working capital turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q2 2026 Calculation
Working capital turnover
= (RevenuesQ2 2026
+ RevenuesQ1 2026
+ RevenuesQ4 2025
+ RevenuesQ3 2025)
÷ Working capital
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals a volatile relationship between working capital levels and the resulting turnover ratio, while revenues remained relatively stable throughout the period from April 2022 to June 2026.
- Working Capital Fluctuations
- Working capital exhibited significant variance, characterized by sharp contractions and expansions. A notable low occurred on April 1, 2023, at 4,325 million USD, followed by a steady climb to a peak of 13,518 million USD by December 31, 2025. This volatility indicates substantial shifts in the balance between current assets and current liabilities over the observed timeframe.
- Revenue Consistency
- Revenues maintained a consistent range, generally fluctuating between 10,345 million USD and 12,215 million USD. The lack of a strong upward or downward linear trend in sales suggests that changes in the working capital turnover ratio were driven primarily by balance sheet adjustments rather than significant growth or decline in top-line performance.
- Working Capital Turnover Trends
- The turnover ratio demonstrated an inverse correlation with working capital levels. A peak efficiency ratio of 10.13 was recorded on April 1, 2023, corresponding with the lowest point of working capital. Conversely, the ratio reached its minimum of 3.30 on December 31, 2025, coinciding with the period of highest working capital investment.
- Efficiency Cycle Analysis
- An initial period of stability was observed in 2022, with ratios hovering between 5.40 and 6.13. Following the 2023 spike, the turnover ratio entered a period of sustained decline and stabilization between 3.64 and 4.87 throughout 2024. The final stages of the period showed increased instability, with the ratio swinging from 3.30 in late 2025 back to 5.59 by June 2026, suggesting an ongoing effort to optimize the utilization of net current assets.
Average Inventory Processing Period
| Jun 27, 2026 | Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Inventory turnover | ||||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||
| Average inventory processing period1 | ||||||||||||||||||||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q2 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The analysis of operational efficiency indicates a significant improvement in inventory management from the second quarter of 2022 through the end of 2023, followed by a stabilization phase spanning 2024 through mid-2026.
- Inventory Turnover Trends
- A consistent upward trajectory is observed from April 2022, where the ratio stood at 3.87, peaking at 5.06 by December 31, 2023. This progression indicates an increased velocity in the movement of goods. Following this peak, the ratio experienced minor fluctuations, oscillating between 4.47 and 5.06, before stabilizing at 4.87 by June 2026.
- Average Inventory Processing Period
- The period required to process inventory shows a corresponding decline, starting at 94 days in April 2022 and reaching a low of 72 days by December 2023. This reduction of 22 days suggests enhanced efficiency in supply chain operations and inventory liquidation. From March 2024 onward, the processing period entered a phase of moderate volatility, reaching a secondary peak of 82 days in June 2025, before settling at a consistent 75 days for the final three quarters of the observed period.
- Operational Correlation and Stability
- An inverse correlation between inventory turnover and the processing period is maintained throughout the analyzed timeframe. The transition from a phase of rapid optimization during 2022 and 2023 to a phase of maintenance between 2024 and 2026 suggests the achievement of an operational equilibrium, effectively balancing inventory holdings against demand to maintain a processing cycle of approximately 75 days.
Average Receivable Collection Period
| Jun 27, 2026 | Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Receivables turnover | ||||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||
| Average receivable collection period1 | ||||||||||||||||||||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q2 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals a gradual deterioration in the efficiency of receivable collections over the observed period. While a temporary improvement in collection efficiency was noted in late 2022, the subsequent trajectory indicates a consistent trend toward longer collection cycles and lower turnover rates.
- Receivables Turnover
- A peak turnover ratio of 5.76 was recorded in October 2022, marking the point of highest efficiency in converting receivables into cash. Following this peak, a steady decline is observed, with the ratio descending to 4.90 by June 2026. This downward trend reflects a reduction in the frequency with which the average receivables balance is collected during the operating cycle.
- Average Receivable Collection Period
- The collection period exhibited initial volatility, reaching a low of 63 days in October 2022 before fluctuating between 66 and 70 days throughout 2023. Starting in early 2024, a gradual upward trend emerged, with the period extending from 68 days to a peak of 74 days by March 2026, where it remained stable through June 2026. This lengthening of the collection window suggests a slowdown in payment receipts from customers.
- Operational Correlation
- A clear inverse correlation is present between the turnover ratio and the collection period. The transition from a turnover ratio of 5.76 to 4.90 corresponds directly with the expansion of the collection period from 63 to 74 days. The convergence of these metrics toward the end of the period suggests an established shift in working capital dynamics, resulting in more capital being tied up in receivables.
Operating Cycle
| Jun 27, 2026 | Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Average inventory processing period | ||||||||||||||||||||||||
| Average receivable collection period | ||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Operating cycle1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Operating Cycle, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q2 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =
2 Click competitor name to see calculations.
The operating cycle exhibited a notable contraction during the initial phase of the observed period, followed by a subsequent period of stabilization and slight expansion. The total cycle length decreased from a peak of 164 days in April 2022 to a low of 142 days by December 2023, indicating an improvement in the efficiency of converting resources into cash.
- Average Inventory Processing Period
- A consistent downward trend was observed from April 2022 through December 2023, as the period declined from 94 days to 72 days. After reaching this trough, the metric entered a phase of volatility, peaking at 82 days in June 2025 before settling at 75 days by June 2026. This component acted as the primary driver of the fluctuations within the total operating cycle.
- Average Receivable Collection Period
- The collection period remained relatively stable throughout the entire timeframe, fluctuating within a narrow range. Following a brief dip to 63 days in October 2022, the period generally trended slightly upward, moving from 70 days in December 2023 to 74 days by June 2026. The relative constancy of this metric suggests a stable credit and collection policy.
- Operating Cycle Synthesis
- The operating cycle experienced an overall reduction of 22 days between April 2022 and December 2023, driven almost exclusively by faster inventory turnover. From 2024 through 2026, the cycle shifted toward a moderate increase, reaching a secondary peak of 156 days in September 2025 before stabilizing at 149 days. The data indicates that while receivable collection times have remained predictable, inventory management has been the variable factor influencing short-term operational liquidity.
Average Payables Payment Period
| Jun 27, 2026 | Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Payables turnover | ||||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||
| Average payables payment period1 | ||||||||||||||||||||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q2 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The analysis of short-term operating activity ratios reveals a cyclical fluctuation in the management of accounts payable over the observed period. A consistent inverse correlation exists between the payables turnover ratio and the average payables payment period, reflecting strategic shifts in the timing of cash outflows to suppliers.
- Payment Period Trends
- The average payables payment period experienced a significant contraction during the initial phase of the analysis, declining from 46 days in April 2022 to a low of 34 days by July 2023. Following this minimum, a sustained upward trend is observed, with the period extending progressively to a peak of 50 days by December 31, 2025. In the first half of 2026, the period showed signs of stabilization, returning to a range between 43 and 46 days.
- Payables Turnover Dynamics
- The payables turnover ratio demonstrates an inverse trajectory to the payment period. The ratio reached its maximum value of 10.82 in July 2023, indicating a high frequency of obligation settlements. Conversely, the ratio declined to its lowest point of 7.27 by December 31, 2025. This decline in turnover corresponds directly with the extension of the payment period, suggesting a reduction in the frequency of supplier payments.
- Working Capital Implications
- The transition from a 34-day payment cycle in mid-2023 to a 50-day cycle by the end of 2025 indicates an operational shift toward the preservation of liquidity. By extending the duration of payables, the organization effectively increases its available working capital. The subsequent moderation in 2026 suggests a realignment of payment terms to maintain a balance between cash flow optimization and supplier relationship management.
Cash Conversion Cycle
| Jun 27, 2026 | Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Average inventory processing period | ||||||||||||||||||||||||
| Average receivable collection period | ||||||||||||||||||||||||
| Average payables payment period | ||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Cash conversion cycle1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q2 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + – =
2 Click competitor name to see calculations.
The cash conversion cycle exhibits a general trend of contraction over the analyzed period, decreasing from 118 days in April 2022 to 106 days by June 2026. While the cycle remains subject to quarterly fluctuations, the overall reduction suggests an improvement in the efficiency of working capital management, primarily driven by optimizations in inventory processing.
- Average Inventory Processing Period
- A sustained downward trend is observed in the time required to process inventory. From a peak of 94 days in April 2022, the period declined to a low of 72 days by December 2023. Although slight increases occurred throughout 2024 and 2025, the period stabilized at 75 days toward the end of the sequence, indicating a permanent shift toward faster inventory turnover compared to the baseline.
- Average Receivable Collection Period
- The collection of receivables remained relatively stable throughout the period. After an initial decrease to 63 days in October 2022, the metric trended slightly upward, settling between 73 and 74 days from March 2025 through June 2026. This suggests a consistent, though slightly lengthening, timeframe for converting credit sales into cash.
- Average Payables Payment Period
- Significant volatility is noted in the payables payment period. The duration fluctuated from a high of 50 days in December 2025 to a low of 34 days in July 2023. The lack of a linear trend suggests that payment strategies are adjusted dynamically, likely in response to liquidity needs or negotiated terms with suppliers.
- Cash Conversion Cycle (CCC)
- The overall CCC fluctuates between a high of 118 days and a low of 97 days. Notable troughs occurred in December 2022 and December 2024, coinciding with periods of lower inventory processing times or extended payables periods. The cycle demonstrates a recurring pattern where gains in inventory efficiency are occasionally offset by fluctuations in payment terms or slight increases in collection times.